238 related articles for article (PubMed ID: 11256075)
1. Ethical and legal implications of pharmacogenomics.
Rothstein MA; Epps PG
Nat Rev Genet; 2001 Mar; 2(3):228-31. PubMed ID: 11256075
[TBL] [Abstract][Full Text] [Related]
2. Human genome project: pharmacogenomics and drug development.
Ganguly NK; Bano R; Seth SD
Indian J Exp Biol; 2001 Oct; 39(10):955-61. PubMed ID: 11883519
[TBL] [Abstract][Full Text] [Related]
3. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
Mandry T
Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
[TBL] [Abstract][Full Text] [Related]
4. Progress in pharmacogenomics and its promise for medicine.
Blake CA; Sobel BE
Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
[TBL] [Abstract][Full Text] [Related]
5. Ethical, social and legal implications of pharmacogenomics: a critical review.
Moldrup C
Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484
[TBL] [Abstract][Full Text] [Related]
6. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
7. What will it take to reap the clinical benefits of pharmacogenomics?
Evans BJ
Food Drug Law J; 2006; 61(4):753-94. PubMed ID: 17180771
[No Abstract] [Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Ethical and legal aspects of clinical trials of drugs.
Stolinová J
Sante Publique (Bucur); 1980; 23(2):115-29. PubMed ID: 7209739
[No Abstract] [Full Text] [Related]
10. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
11. Can pharmacogenomics make a difference in drug development?
Ledley FD
Nat Biotechnol; 1999 Aug; 17(8):731. PubMed ID: 10429218
[No Abstract] [Full Text] [Related]
12. Ethics and policy perspectives on personalized medicine in the post-genomic era.
Landon MR
J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics in cardiovascular clinical trials.
Shah R; Darne B; Atar D; Abadie E; Adams KF; Zannad F;
Fundam Clin Pharmacol; 2004 Dec; 18(6):705-8. PubMed ID: 15548243
[TBL] [Abstract][Full Text] [Related]
14. Exploring emerging technologies using metaphors--a study of orphan drugs and pharmacogenomics.
Boon W; Moors E
Soc Sci Med; 2008 May; 66(9):1915-27. PubMed ID: 18308439
[TBL] [Abstract][Full Text] [Related]
15. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
Lesko LJ; Woodcock J
Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics. Going from genome to pill.
Service RF
Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
[No Abstract] [Full Text] [Related]
17. [Pharmacogenomics: the quest for individualized therapy].
López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
[TBL] [Abstract][Full Text] [Related]
18. 4th Annual Pharmacogenomics and Medicine Lectures.
Oestreicher P
Pharmacogenomics; 2001 Aug; 2(3):291-6. PubMed ID: 11939134
[TBL] [Abstract][Full Text] [Related]
19. Regulatory agency consideration of pharmacogenomics.
Pendergast MK
Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
[TBL] [Abstract][Full Text] [Related]
20. [Contributions of pharmacogenomics to enhance the efficiency of randomized clinical trials].
de Jesús Castillejos-López M; García-Sancho MC; Torres-Espíndola LM; Pérez-Padilla JR
Rev Invest Clin; 2006; 58(5):512-24. PubMed ID: 17408112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
